24-hour efficacy of the bimatoprost–timolol fixed combination versus latanoprost as first choice therapy in subjects with high-pressure exfoliation syndrome and glaucoma

Konstas, Anastasios G. P.; Holló, Gábor; Mikropoulos, Dimitrios G.; Haidich, Anna Bettina; Dimopoulos, A. T.; Empeslidis, Theodoros; Teus, Miguel A.; Ritch, Robert

doi:10.1136/bjophthalmol-2012-302843

Cited by 19 publications

(13 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In relation to glaucoma medication, it was reported that prostaglandin could make IOP fluctuation smaller than without medication in PE patients. 32 However, more than 2 glaucoma medications were prescribed for all patients in the PE group patients, IOP fluctuation could larger than healthy group who did not drop any glaucoma medication. Hollo´et al 30 reported that the CLS technique cannot be clinically used to monitor the IOP decrease induced by topical medication in glaucoma.…”

Section: Discussionmentioning

confidence: 99%

Fluctuations of the Intraocular Pressure in Pseudoexfoliation Syndrome and Normal Eyes Measured by a Contact Lens Sensor

Tojo

Hayashi

Otsuka

et al. 2016

Journal of Glaucoma

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Fluctuations of the Intraocular Pressure in Pseudoexfoliation Syndrome and Normal Eyes Measured by a Contact Lens Sensor

Tojo

Hayashi

Otsuka

et al. 2016

Journal of Glaucoma

View full text Add to dashboard Cite

show abstract

“…A 2013 randomized, observer-masked study (Konstas et al) compared BTFC to LM as initial therapy in 41 patients with newly diagnosed, previously untreated exfoliation syndrome or exfoliative glaucoma, and baseline morning IOP >29 mmHg 10. Twenty-four-hour IOP was measured at baseline and at 3 and 6 months, with treatment groups crossed over at 3 months to the alternate therapy.…”

Section: Discussionmentioning

confidence: 99%

Bimatoprost/timolol fixed combination versus latanoprost in treatment-naïve glaucoma patients at high risk of progression: a pilot study

Gutiérrez‐Díaz¹,

Cotta²,

Muñoz‐Negrete³

et al. 2014

OPTH

View full text Add to dashboard Cite

ObjectiveTo compare a fixed combination of 0.03% bimatoprost and 0.5% timolol (BTFC) with latanoprost monotherapy (LM) in treatment-naïve patients with open-angle glaucoma (OAG) and risk factors for glaucomatous progression.MethodsPatients were enrolled at 15 sites in Spain and Portugal, and were randomized 1:1 to BTFC or LM. Patients instilled one drop of medication once per day at 8 pm for 12 weeks. The primary outcome was change in intraocular pressure (IOP) at 12 weeks.ResultsOf 81 patients enrolled, 43 were randomized to BTFC and 38 to LM. Mean (SD) change in IOP from baseline to 12 weeks was significantly greater for BTFC than for LM: −13.5 mmHg (4.48) versus −11.4 mmHg (3.19), respectively (P=0.003). Similarly, at 12 weeks, significantly more BTFC patients than LM patients had IOP reductions of ≥40% (74.4% versus 47.4%, P=0.015) or ≥50% (46.5% versus 15.8%, P=0.003). Adverse events were more frequent with BTFC than with LM (33 versus 13 events), but most were mild in severity. The only serious adverse event (colon cancer) was adjudged unrelated to the study medication.ConclusionBTFC was effective and well tolerated in treatment-naïve patients with OAG at high risk of progression.

show abstract

“…The same group found that bimatoprost provides better diurnal control of IOP than latanoprost in pseudoexfoliation patients with high baseline IOP (49). They additionally reported that the fixed combination of bimatoprost-timolol outperformed either bimatoprost or latanoprost alone in IOP reduction in these same ocular hypertensive pseudoexfoliation patients (50, 51). …”

Section: Treatmentmentioning

confidence: 93%

Genetics, Diagnosis, and Monitoring of Pseudoexfoliation Glaucoma

Nathan

Kuchtey

2016

Curr Ophthalmol Rep

View full text Add to dashboard Cite

Recent studies have shed new light on the genetic factors underlying pseudoexfoliation syndrome, growing our understanding of the role of the lysyl oxidase-like 1 (LOXL1) gene and its various polymorphisms as well as identifying new genetic associations. Recent years have brought new insight on how these genetic factors interact with other factors, including environmental, to confer risk to individuals and populations worldwide. All of these findings may hold importance to the screening, diagnosis, and monitoring of pseudoexfoliation and may also help lead to the identification of novel therapeutic targets. This review serves as an update on the recent trends and findings in pseudoexfoliation syndrome.

show abstract

24-hour efficacy of the bimatoprost–timolol fixed combination versus latanoprost as first choice therapy in subjects with high-pressure exfoliation syndrome and glaucoma

Abstract: As first choice therapy in high-pressure, at-risk exfoliation patients, BTFC controlled mean 24-h IOP significantly better than latanoprost monotherapy.

Cited by 19 publications

References 29 publications

Fluctuations of the Intraocular Pressure in Pseudoexfoliation Syndrome and Normal Eyes Measured by a Contact Lens Sensor

Fluctuations of the Intraocular Pressure in Pseudoexfoliation Syndrome and Normal Eyes Measured by a Contact Lens Sensor

Bimatoprost/timolol fixed combination versus latanoprost in treatment-naïve glaucoma patients at high risk of progression: a pilot study

Genetics, Diagnosis, and Monitoring of Pseudoexfoliation Glaucoma

Contact Info

Product

Resources

About

24-hour efficacy of the bimatoprost–timolol fixed combination versus latanoprost as first choice therapy in subjects with high-pressure exfoliation syndrome and glaucoma

Abstract: As first choice therapy in high-pressure, at-risk exfoliation patients, BTFC controlled mean 24-h IOP significantly better than latanoprost monotherapy.

Cited by 19 publications

References 29 publications

Fluctuations of the Intraocular Pressure in Pseudoexfoliation Syndrome and Normal Eyes Measured by a Contact Lens Sensor

Fluctuations of the Intraocular Pressure in Pseudoexfoliation Syndrome and Normal Eyes Measured by a Contact Lens Sensor

Bimatoprost/timolol fixed combination versus latanoprost in treatment-na&iuml;ve glaucoma patients at high risk of progression: a pilot study

Genetics, Diagnosis, and Monitoring of Pseudoexfoliation Glaucoma

Contact Info

Product

Resources

About

Bimatoprost/timolol fixed combination versus latanoprost in treatment-naïve glaucoma patients at high risk of progression: a pilot study